|
|
Volumn 4, Issue 8, 2007, Pages 458-459
|
|
Sunitinib - A new standard of care for metastatic renal cell carcinoma: Commentary
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHA INTERFERON;
BEVACIZUMAB;
INTERLEUKIN 2;
PLACEBO;
PLATELET DERIVED GROWTH FACTOR;
SORAFENIB;
SUNITINIB;
TEMSIROLIMUS;
VASCULOTROPIN RECEPTOR;
ADVANCED CANCER;
CANCER GRADING;
CANCER SURVIVAL;
CHILL;
CLEAR CELL CARCINOMA;
CLINICAL TRIAL;
DIARRHEA;
DISEASE FREE SURVIVAL;
DRUG APPROVAL;
DRUG CHOICE;
DRUG DOSE TITRATION;
DRUG MEGADOSE;
DRUG SAFETY;
DRUG TARGETING;
FATIGUE;
FEVER;
FLU LIKE SYNDROME;
FREQUENCY ANALYSIS;
HAND FOOT SYNDROME;
HUMAN;
HYPERTENSION;
KIDNEY CARCINOMA;
LEUKOPENIA;
LOW DRUG DOSE;
LYMPHOCYTOPENIA;
METASTASIS POTENTIAL;
MULTIPLE CYCLE TREATMENT;
MYALGIA;
NEUTROPENIA;
PRIORITY JOURNAL;
QUALITY OF LIFE;
SHORT SURVEY;
SIDE EFFECT;
SYMPTOM;
THROMBOCYTOPENIA;
TREATMENT RESPONSE;
TREND STUDY;
UNSPECIFIED SIDE EFFECT;
VOMITING;
|
|
EID: 34548577466
PISSN: 17434254
EISSN: 17434262
Source Type: Journal
DOI: 10.1038/ncponc0882 Document Type: Short Survey |
|
Times cited : (2)
|
|
References (5)
|
